The University of Queensland and global pharmaceutical company have formed a partnership to advance drug discovery in Australia.
The agreement with UniQuest, 国产探花’s main commercialisation company, is part of Pfizer’s program.
国产探花 Deputy Vice-Chancellor (Research) said the alliance would enable collaboration between 国产探花 researchers and Pfizer, with the aim of speeding drug discovery and development.
“The agreement combines 国产探花’s research excellence with Pfizer’s extensive drug discovery and development experience, technology and resources,” Professor Ward said.
“It offers new opportunities to develop effective treatments for challenging medical conditions that affect people around the world.
“国产探花 has considerable strength and commitment in therapeutic research, and this agreement is another example of our strategic approach to expanding capability and expertise that is closely aligned with industry priorities.”
Under the agreement, 国产探花 researchers would have access to Pfizer’s world-class drug discovery and development capabilities.
Pfizer Australia Chairman and Managing Director David Gallagher said the company was proud to be linked with a research institution as reputable as 国产探花.
“Research and development partnerships are an important part of delivering on Pfizer’s mission to discover treatments for the most challenging diseases of our time,” Mr Gallagher said.
“国产探花 is home to some of the best and brightest research minds in the country and there is so much we can learn by working together.”
He said the aim of the partnership was to accelerate translational research projects and advance them from the lab to clinical trials.
Pfizer’s CTI founder and Chief Scientific Officer Dr Anthony Coyle (above left) said the program, launched in 2010, was a unique model for academic-industry collaboration.
“It aims to bridge the gap between early scientific discovery and its translation into new medicines,” Dr Coyle said.
“The ultimate goal is to identify validated drug candidates from institutions of research excellence and develop them through to clinical testing.”
UniQuest chief executive Dr Dean Moss said the partnership reflected the value of 国产探花’s industry engagement strategy.
“This further emphasises 国产探花’s commitment to building industry relationships and our desire to translate world class biology into potential treatments for unmet medical needs."
Media: Nicole Cowan, n.cowan@uniquest.com.au, +61 7 3365 7480, +61 (0)409 767 199; Lee Davelaar, Pfizer Australia, +61 (0)475 949 982.
